Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in npj Precision Oncology highlighting the power of its ultrasensitive molecular residual disease (MRD) assay, NeXT Personal®, in monitoring immunotherapy response across a broad range of advanced cancers. The study, titled "Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer," wa.

Business Wire • Feb 2, 2026

Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 at the Cliff Lodge in Snowbird, UT. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new par.

Business Wire • Jan 28, 2026

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the early access launch of Real-Time Variant Tracker, a powerful new option added to its ultrasensitive NeXT Personal molecular residual disease (MRD) test designed to detect small traces of circulating tumor DNA (ctDNA) in the blood that represent residual or recurrent cancer. Clinicians using the NeXT Personal MRD test will now be able to opt-in for additional reporting.

Business Wire • Jan 12, 2026

Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported certain unaudited preliminary financial and operational results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter Strategic and Operational Highlights Secured Milestone Medicare Coverage: Received Medicare coverage approval for the surveillance of cancer recurrence in breast cancer patients, a key catalyst for clinical revenue and mar.

Business Wire • Jan 8, 2026

Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR). The paper, titled "Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy," details results from Dr. Rodrigo Toledo and a leading team at the Vall d'Hebron Institute of Oncology (VHIO).

Business Wire • Dec 17, 2025

New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of one of the largest and most comprehensive patient cohorts to date from the landmark TRACERx study, in the journal Cell. The study, titled "Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction," demonstrates the clinical importance of ultrasensitive, tumor-informed molecular residual disease (MRD) testi.

Business Wire • Dec 11, 2025

Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at the Lotte New York Palace in New York, NY. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guidi.

Business Wire • Nov 18, 2025

Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage of its ultrasensitive NeXT Personal® test for surveillance of cancer recurrence in breast cancer patients. This milestone marks an important step forward in cancer surveillance, offering a powerful tool for doctors and breast cancer patients. Medicare beneficiaries with stage II and III breast cancer, including the three major subtypes HR+/HE.

Business Wire • Nov 10, 2025

Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript

Personalis, Inc. ( PSNL ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Christopher Hall - President, CEO & Director Aaron Tachibana - CFO & COO Richard Chen - Executive VP of R&D and Chief Medical Officer Conference Call Participants Caroline Corner - Westwicke Partners, LLC Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Mark Massaro - BTIG, LLC, Research Division Daniel Brennan - TD Cowen, Research Division Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Michael Matson - Needham & Company, LLC, Research Division John Wilkin - Craig-Hallum Capital Group LLC, Research Division Yu He - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Personalis Third Quarter 2025 Earnings Conference.

Seeking Alpha • Nov 5, 2025

Personalis Reports Third Quarter 2025 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2025. The quarter was distinguished by significant operational momentum in its "Win-in-MRD" strategy, headlined by increasing clinical tests delivered and robust clinical evidence generation. Third Quarter 2025 and Recent Business Highlights Accelerated Clinical Adoption: Delivered 4,388 clinical tests.

Business Wire • Nov 4, 2025